Filing Details

Accession Number:
0000899243-20-007676
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-09 19:37:35
Reporting Period:
2020-03-05
Accepted Time:
2020-03-09 19:37:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1629137 Global Blood Therapeutics Inc. GBT Pharmaceutical Preparations (2834) 274825712
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1789673 Joshua Lehrer-Graiwer C/O Global Blood Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300
South San Francisco CA 94080
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-03-05 1,138 $65.30 2,595 No 4 S Direct
Common Stock Acquisiton 2020-03-09 938 $19.89 3,533 No 4 M Direct
Common Stock Disposition 2020-03-09 938 $59.90 2,595 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-03-09 938 $0.00 938 $19.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,875 2026-09-07 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. Represents the weighted average sale price of the shares sold ranging from $59.80 to $60.00 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.